期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

新型红细胞生成刺激剂的现状与展望 被引量：5

下载PDF
导出
摘要 贫血是慢性肾衰竭（chronic renal failure，CRF）患者最常见的并发症之一，虽然其病因是多种多样的，但是红细胞生成素（erythropoietin，EPO）的不足仍是其首要病因。在红细胞生成刺激剂（erythropoiesis—stimulatlng agents，ESA）问世以前，肾性贫血的患者只能依靠输血治疗。
作者 徐潇漪 谌贻璞
机构地区 首都医科大学附属北京安贞医院肾内科
出处 《中国血液净化》 2010年第9期467-470,共4页 Chinese Journal of Blood Purification
关键词 红细胞生成素 刺激剂 肾性贫血 慢性肾衰竭 输血治疗 并发症 患者 病因
分类号 R692.5 [医药卫生—泌尿科学]
  • 相关文献

参考文献44

  • 1Locatelli F, Nissenson AR, Barrett BJ, et al. Clinical practice guidelines for anemia in chronic kidney disease: problems and solutions. A position statement from Kidney Disease: Improving Global Outcomes (KDIGO)[J]. Kidney lnt, 2008.74:1237- 1240.
  • 2Finkelstein FO, Story K, Firanek C, et al. Healthrelated quality of life and hemoglobin levels in chronic kidney disease patients[J]. Clin J Am Soc Nephrol, 2009,4:33 38.
  • 3Ayus JC, Go AS, Valderrabano F, et al. Effects of erythro poietin on left ventricular hypertrophy in adults with severe chronic renal failure and hemoglobin <10 g/dL[J]. Kidney Int, 2005,68:788-795.
  • 4Go AS, Yang J, Ackerson LM, et al. Hemoglobin level chronic kidney disease, and the risks of death and hospi talization in adults with chronic heart failure: the Ane mia in Chronic Heart Failure: Outcomes and Resource Utili zation (ANCHOR) Study[J]. Circulation, 2006, 113:2713-2723.
  • 5Schiller B, Doss S, E DEC, et al. Costs of managing anemia with erythropoiesis stimulating agents during hemodialysis: a time and motion study[J], Hemodial Int, 2008,12:441- 449.
  • 6Miyake T, Kung CK, Ooldwasser E. Purification of human erythropoietin[J]. J Biol Chem, 1977,252:5558 -5564.
  • 7Jaeobs K, Shoemaker C, Rudersdorf R, et al. Isolation and characterization of genomic and cDNA clones of human erythropoietin[J]. Nature, 1985,313:806- 810.
  • 8Eschbach JW, Egrie JC, Downing MR, et al. Correction of the anemia of end stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial[J]. N Eagl J Med, 1987, 316:73- 78.
  • 9Macdougall IC, Gray SJ, Elston O, eta]. Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients[J]. J Am Soc Nephrol, 1999, 10:2392 -2395.
  • 10Bailon P, Pahlke W, Brandt M, et al. CERA (continuous erythropoiesis receptor activator) for the treatment of renal anemia: A new agent with an innovative mechanism of action[J]. Nephrol Dial Transplant, 2003,166 suppl 4.

同被引文献54

  • 1Locatelli F, Nissenson AR, Barrett BJ, et al. Clinical practice guidelines for anemia in chronic kidney disease: Problems and solutions. A position statement from Kidney Disease: Improving Global Outcomes(KD100)[J]. Kidney International, 2008,74:1237-1240.
  • 2Thorp ML, Johnson ES, Yang X, et al. Effect of anaemia on mortality, cardiovascular hospitalizations and end-stage renal disease among patients with chronic kidney disease [J]. Nephrology (Carlton), 2008,14:240-246.
  • 3Foley RN. Emerging erythropoiesis-stimulating agents. Nat Rev Nephrol, 2010,6:218-223.
  • 4Singh AK. What is causing the mortality in treating the anemia of chronic kidney disease: erythropoietin dose or hemoglobin level[J]? Curr Opin Nephrol Hypertens, 2010, 19:420-424.
  • 5Macdougall IC. Iron supplementation in the non-dialysis chronic kidney disease (ND-CKD) patient:Oral or intravenous? [J]. Curt Med Res Opin, 2010,26:473-82.
  • 6Anderson GJ, Frazer DM, McLaren GD. Iron absorption and metabolism[J]. Curt Opin Gastroenterol, 2009,25:129-135.
  • 7Locatelli F, Nissenson AR,Barrett BJ,et al. Clinical practiceguidelines for anemia in chronic kidney disease: problems andsolutions. A position statement from Kidney Disease: Impro-ving Global Outcomes (KDIGO) [J] . Kidney Int, 2008, 74:1237-1 240.
  • 8Siddique MS. Fernandes HM, Wooldridge TD,et al. Reversibleischemia around intracerebral hemorrhage: a single-photon e-mission computerized tomography study [JJ. Journal of Neuro-surgery ,2002, 96(4):736-741.
  • 9Finkelstein FO,Story K,Firanek C,et al. Health relatedquality of life and hemoglobin levels in chronic kidney diseasepatients[J]. Clin J Am Soc Nephrol, 2009,4:33 38.
  • 10Ehrenreich H, Hasselblatt Dembowski C,et al. Erythro-poietin therapy for acute stroke is both safe and beneficial[J].Molecular Medicine,2002,8(8) : 495-505.

引证文献5

二级引证文献15

中国血液净化
2010年 第9期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部